Journal Mobile Options
Table of Contents
Vol. 18, No. 2, 2004
Issue release date: August 2004

Autoimmune Responses to Amyloid Structures of Aβ(25–35) Peptide and Human Lysozyme in the Serum of Patients with Progressive Alzheimer’s Disease

Gruden M.A. · Davudova T.B. · Mališauskas M. · Zamotin V.V. · Sewell R.D.E. · Voskresenskaya N.I. · Kostanyan I.A. · Sherstnev V.V. · Morozova-Roche L.A.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


We have found an increased level of serum antibodies to the prefibrillar structures of both Aβ(25–35) peptide and human lysozyme in Alzheimer’s disease (AD) patients compared to age-matched controls, indicating that autoimmunity is implicated in AD. In the serum of AD patients with a long-term duration (>15 years) the titer of serum antibodies to aggregates of Aβ(25–35) peptide increased by approximately 5-fold, whilst the antibody titer to lysozyme protofilaments decreased by approximately 8-fold compared to patients with AD duration of <5 years. The content of immunoglobulins of the A, G and M types declined, particularly in AD duration of >15 years. An increase in the concentration of immune complexes and higher lysozyme activity was detected in the serum of all patients and this was suggestive of an inflammatory reaction. We propose that the autoimmune response to different amyloid structures in AD can be viewed as a clearance pathway targeting amyloid development. Autoimmune response can be exploited as a marker of ongoing protein aggregation and hence be used as a diagnostic feature of AD.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Selkoe DJ: Alzheimer’s disease: Genotypes, phenotypes, and treatments. Science 1997;275:630–631.
  2. Neve RL, Robakis NK: Alzheimer’s disease: A re-examination of the amyloid hypothesis. Trends Neurosci 1998;21:15–19.
  3. Vagnucci AH Jr, Li WW: Alzheimer’s disease and angiogenesis. Lancet 2003;361:605–608.
  4. Tarkowski E, Andreasen N, Tarkowski A, Blennow K: Intrathecal inflammation precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2003;74:1200–1205.
  5. Singh VK: Neuroautoimmunity: Pathogenic implications for Alzheimer’s disease. Gerontology 1997;43:79–94.
  6. McGeer PL, McGeer EG: Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 2001;22:799–809.
  7. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486–489.
  8. Su Y, Chang PT: Acidic pH promotes the formation of toxic fibrils from beta-amyloid peptide. Brain Res 2001;893:287–291.
  9. Weksler ME, Goodhardt M: Do age-associated changes in ‘physiologic’ autoantibodies contribute to infection, atherosclerosis, and Alzheimer’s disease? Exp Gerontol 2000;37:971–979.
  10. Morozova-Roche LA, Zurdo J, Spencer A, Noppe W, Receveur V, Archer DB, Joniau M, Dobson CM: Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants. J Struct Biol 2000;130:339–343.
  11. Malisauskas M, Zamotin V, Jass J, Noppe W, Dobson CM, Morozova-Roche LA: Amyloid protofilaments from the calcium-binding protein equine lysozyme: Formation of ring and linear structures depends on pH and metal ion concentration. J Mol Biol 2003;330:879–890.
  12. Dobson CM: Protein folding and misfolding. Nature 2003;426:884–890.
  13. Effors RB: Ageing and the immune system. Novartis Found Symp 2001;235:130–139.
  14. Moulias R, Raynaud-Simon A, Moulias S, Meaume S: Immunity, autoimmunity, and the aging process: Complex interactions. Ann Méd Interne (Paris) 2002;153:441–445.
  15. Melrose J, Ghosh P, Taylor TK: Lysozyme, a major low-molecular-weight cationic protein of the intervertebral disc, which increases with ageing and degeneration. Gerontology 1989;35:173–180.
  16. Kelly JW: Mechanisms of amyloidogenesis. Nat Struct Biol 2000;7:824–826.
  17. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M: Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002;416:507–511.
  18. Harrison RF, Hawkins PN, Roche WR, MacMahon RF, Hubscher SG, Buckels JA: ‘Fragile’ liver and massive hepatic haemorrhage due to hereditary amyloidosis. Gut 1996;38:151–152.
  19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  20. Folstein M, Folstein S, McHugh P: ‘Mini-mental state’: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  21. Wallin A, Blennow K: The clinical diagnosis of vascular dementia. Dementia 1994;5:181–184.
  22. Noppe W, Hanssens I, De Cuyper M: Simple two-step procedure for the preparation of highly active pure equine milk lysozyme. J Chromatogr A 1996;719:327–331.
  23. Wang Z, Zhou C, Wang C, Wan L, Fang X, Bai C: AFM and STM study of beta-amyloid aggregation on graphite. Ultramicroscopy 2003;97:73–79.
  24. Rich RR, Fleisher TA, Shearer WT, Kotzin A (eds): Clinical Immunology: Principles and Practice. St Louis, Mosby, 2001.
  25. Manchini G, Carbonara AG, Heremans JF: Immunochemical quantitation of antigens by single radial diffusion. Immunochemistry 1965;2:235–254.
  26. Maskova Y, Kaslik G, Riba I, et al: Simple method of circulating immune complexes detection in human sera by polyethylene glycol precipitation. J Immun Forsch 1978;154:399–405.
  27. Chamberlain AK, MacPhee CE, Zurdo J, Morozova-Roche LA, Hill HA, Dobson CM, Davis JJ: Ultrastructural organization of amyloid fibrils by atomic force microscopy. Biophys J 2000;79:3282–3293.
  28. Dodel RC, Hampel H, Du Y: Immunotherapy for Alzheimer’s disease. Lancet Neurol 2003;2:215–220.
  29. Janus C: Vaccines for Alzheimer’s disease: How close are we? CNS Drugs 2003;17:457–474.
  30. Lashuel HA, Hartley DM, Petre BM, Wall JS, Simon MN, Walz T, Lansbury PT Jr: Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol 2003;332:795–808.
  31. Stine WB Jr, Dahlgren KN, Krafft GA, LaDu MJ: In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 2003,278:11612–11622.
  32. Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR, Roher AE: Amyloid-beta peptides interact with plasma proteins and erythrocytes: Implications for their quantitation in plasma. Biochem Biophys Res Commun 2000;268:750–756.
  33. Harpin ML, Delaere P, Javoy-Agid F, Bock E, Jacque C, Delpech B, Villarroya H, Duyckaerts C, Hauw JJ, Baumann N: Glial fibrillary acidic protein and beta A4 protein deposits in temporal lobe of aging brain and senile dementia of the Alzheimer type: Relation with the cognitive state and with quantitative studies of senile plaques and neurofibrillary tangles. J Neurosci Res 1990;27:587–594.
  34. Caughey B, Lansbury PT: Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003;26:267–298.
  35. van Beek J, Elward K, Gasque P: Activation of complement in the central nervous system: Roles in neurodegeneration and neuroprotection. Ann NY Acad Sci 2003;992:56–71.
  36. Davies KA, Hird V, Stewart S, Sivolapenko GB: A study of in vivo immune complex formation and clearance in man. J Immunol 1990;144:4613–4620.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50